Ifupinostat API is a pharmaceutical-grade Histone Deacetylase (HDAC) inhibitor being developed as a targeted anticancer therapy. HDAC inhibition promotes the reactivation of tumor suppressor genes, induces apoptosis, inhibits cancer cell proliferation, and enhances antitumor immune responses.
Ifupinostat is currently under clinical investigation for the treatment of hematological malignancies and solid tumors, particularly as part of combination therapy with other anticancer agents. Its targeted mechanism of action makes it a promising candidate for next-generation oncology treatments.
Manufactured under WHO-GMP-certified facilities, our Ifupinostat API is produced with stringent quality standards to ensure high purity, stability, and batch-to-batch consistency. Every batch is supplied with complete documentation, including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and Product Specifications.
Ifupinostat API is being developed for targeted oncology therapies and is under clinical investigation for the treatment of various cancers.
It inhibits histone deacetylase (HDAC) enzymes, promoting tumor suppressor gene expression, inducing apoptosis, and inhibiting cancer cell growth.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation.
Yes. We supply Ifupinostat API in commercial quantities for pharmaceutical research and development, subject to applicable regulatory requirements.
Get Bulk Quote via WhatsApp